Differentiating systemic lupus erythematosus from other diseases: Difference between revisions

Jump to navigation Jump to search
Line 32: Line 32:
! align="center" style="background:#4479BA; color: #FFFFFF;" |Anti-dsDNA
! align="center" style="background:#4479BA; color: #FFFFFF;" |Anti-dsDNA
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]]
| colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]]
|
|
|
|
Line 49: Line 49:
|
|
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |[[Rheumatoid arthritis]] ([[Rheumatoid arthritis|RA]])
| colspan="2" align="center" style="background:#DCDCDC;" |[[Rheumatoid arthritis]] ([[Rheumatoid arthritis|RA]])
| +
| +
| +
| +
Line 64: Line 64:
| +
| +
|
|
*
|
|
*  
*  
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |Rhupus
| colspan="2" align="center" style="background:#DCDCDC;" |Rhupus
| +
| +
| +
| +
Line 83: Line 82:
| +
| +
|
|
* Patients with overlapping features of both SLE and [[Rheumatoid arthritis|RA]]
|Erosive [[arthropathy]]
* Serologies consistent with both SLE and [[Rheumatoid arthritis|RA]]
|
* Erosive [[arthropathy]] that is atypical for SLE
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |[[Mixed connective tissue disease]] (MCTD)<ref name="pmid21959290">{{cite journal |vauthors=Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M |title="To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity |journal=Semin. Arthritis Rheum. |volume=41 |issue=4 |pages=589–98 |year=2012 |pmid=21959290 |doi=10.1016/j.semarthrit.2011.07.010 |url=}}</ref>
| colspan="2" align="center" style="background:#DCDCDC;" |[[Mixed connective tissue disease]] (MCTD)<ref name="pmid21959290">{{cite journal |vauthors=Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M |title="To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity |journal=Semin. Arthritis Rheum. |volume=41 |issue=4 |pages=589–98 |year=2012 |pmid=21959290 |doi=10.1016/j.semarthrit.2011.07.010 |url=}}</ref>
|
|
|
|
Line 103: Line 99:
| +
| +
|
|
* A mix disease with overlapping features of SLE, [[systemic sclerosis]] (SSc), and [[polymyositis]] (PM)
|Overlapping features of SLE, [[systemic sclerosis]] (SSc), and [[polymyositis]] (PM)
* [[Antibodies]] against U1 ribonucleoprotein (RNP)
|
*
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |[[Undifferentiated connective tissue disease]] (UCTD)
| colspan="2" align="center" style="background:#DCDCDC;" |[[Undifferentiated connective tissue disease]] (UCTD)
| +
| +
|
|
|
|
|
|
|Small and large joints
|Lower extremity
|↑
|↑
|↑
|↑
Line 122: Line 115:
|
|
| +
| +
|erythematous macules, patches, or papules with delicate scale
mostly in lower extremities
|
|
* erythematous macules, patches, or papules with delicate scale
*  
* mostly in lower extremities
|
* sclerodactyly
* telangiectasias
* calcinosis
* malignant hypertension
* acute renal failure
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic sclerosis]] (SSc)
| colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic sclerosis]] (SSc)
|<nowiki>+/-</nowiki>
|<nowiki>+/-</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
Line 146: Line 135:
|↑
|↑
| +
| +
|
|skin thickening and hardening and edematous swelling and erythema
* skin thickening and hardening
|[[Sclerodactyly]], [[Telangiectasias]], [[Calcinosis]], [[Malignant hypertension]], [[acute renal failure]]
* Edematous swelling and erythema
|
* [[Sclerodactyly]]
* [[Telangiectasias]]
* [[Calcinosis]]
* [[Malignant hypertension]]
* [[acute renal failure]]
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |Sjögren’s syndrome
| colspan="2" align="center" style="background:#DCDCDC;" |Sjögren’s syndrome
15485020
15485020
|<nowiki>+/-</nowiki>
|<nowiki>+/-</nowiki>
Line 174: Line 156:
|
|
|
|
|
|xerosis, scaly skin, annular erythema
* Xerosis
* Scaly skin
* Annular erythema


|
|[[Keratoconjunctivitis sicca]], [[Xerostomia]]
* [[Keratoconjunctivitis sicca]]
* [[Xerostomia]]
|-
|-
| rowspan="3" align="center" style="background:#DCDCDC;" |Vasculitis
| rowspan="3" align="center" style="background:#DCDCDC;" |Vasculitis
| align="center" style="background:#DCDCDC;" |Giant cell
| align="center" style="background:#DCDCDC;" |Giant cell
|
|
Line 197: Line 174:
|
|
|
|
| rowspan="3"|
| rowspan="3" |
|
|Rare
* Rare
|Involvement of ranial branches of arteries, visual loss
|
* cranial branches of arteries
* visual loss
|-
|-
| align="center" style="background:#DCDCDC;" |[[Takayasu's arteritis|Takayasu]]
| align="center" style="background:#DCDCDC;" |[[Takayasu's arteritis|Takayasu]]
Line 242: Line 216:
|
|
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |Behçet’s syndrome
| colspan="2" align="center" style="background:#DCDCDC;" |Behçet’s syndrome
|<nowiki>+/-</nowiki>
|<nowiki>+/-</nowiki>
|<nowiki>+/-</nowiki>
|<nowiki>+/-</nowiki>
Line 264: Line 238:
* [[ANA]]-negative
* [[ANA]]-negative
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |Kikuchi’s disease
| colspan="2" align="center" style="background:#DCDCDC;" |Kikuchi’s disease
|
|
|<nowiki>+/-</nowiki>
|<nowiki>+/-</nowiki>
Line 286: Line 260:
* May be associated with SLE
* May be associated with SLE
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |Serum sickness
| colspan="2" align="center" style="background:#DCDCDC;" |Serum sickness
|<nowiki>+/-</nowiki>
|<nowiki>+/-</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
Line 307: Line 281:
* Self-limited
* Self-limited
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |Psoriatic arthritis
| colspan="2" align="center" style="background:#DCDCDC;" |Psoriatic arthritis
|
|
|
|
Line 324: Line 298:
|
|
|-
|-
| colspan="2" align="center" style="background:#DCDCDC;" |Human [[parvovirus]] B19 infection
| colspan="2" align="center" style="background:#DCDCDC;" |Human [[parvovirus]] B19 infection
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>

Revision as of 19:34, 11 July 2017


Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Differentiating systemic lupus erythematosus from other diseases On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Differentiating systemic lupus erythematosus from other diseases

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Differentiating systemic lupus erythematosus from other diseases

on Differentiating systemic lupus erythematosus from other diseases

Differentiating systemic lupus erythematosus from other diseases in the news

Blogs onDifferentiating systemic lupus erythematosus from other diseases

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Differentiating systemic lupus erythematosus from other diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overview

Systemic lupus erythematosus (SLE) must be differentiated from other diseases that cause skin rash, arthritis, positive autoimmune serology, weight loss, fevers and chronic pain, such as rheumatoid arthritis(RA), mixed connective tissue disease (MCTD), systemic sclerosis (SSc), dermatomyositis (DM), polymyositis(PM), and other autoimmune diseases.

Differentiating systemic lupus erythematosus from other diseases

Systemic lupus erythematosus (SLE) must be differentiated from other diseases that cause skin rash, arthritis, positive autoimmune serology, weight loss, fevers and chronic pain, such as rheumatoid arthritis(RA), mixed connective tissue disease (MCTD), systemic sclerosis (SSc), dermatomyositis (DM), polymyositis(PM), and other autoimmune diseases.

Differetiating SLE from other diseases that cause arthritis and rash
n Arthritis Auto-antibodies Raynaud phenamon Rash pattern Distinguishing/specific features
Polyarthritis Tenderness Edema Deformity /Erosion Pattern ANA RF Anti-CCp anti U1RNP AntiSm AntiRo Anti-dsDNA
Systemic lupus erythematosus Small joints
Rheumatoid arthritis (RA) + + + + Small and large joints ↑↑ ↑↑ +
Rhupus + + + + Small and large joints + Erosive arthropathy
Mixed connective tissue disease (MCTD)[1] + Small and large joints ↑↑ + Overlapping features of SLE, systemic sclerosis (SSc), and polymyositis (PM)
Undifferentiated connective tissue disease (UCTD) + Lower extremity + erythematous macules, patches, or papules with delicate scale

mostly in lower extremities

Systemic sclerosis (SSc) +/- + + +/- ↑↑ + skin thickening and hardening and edematous swelling and erythema Sclerodactyly, Telangiectasias, Calcinosis, Malignant hypertension, acute renal failure
Sjögren’s syndrome

15485020

+/- +/- Lower extremity

and

axiallary creases

xerosis, scaly skin, annular erythema Keratoconjunctivitis sicca, Xerostomia
Vasculitis Giant cell + + Rare Involvement of ranial branches of arteries, visual loss
Takayasu +/- +/-
  • Erythema nodosum
  • Pyoderma gangrenosum
Poly-arteritis nodosa +/-
  • tender erythematous nodules
  • Purpura
  • Livedo reticularis
  • Bullous or vesicular eruption
Behçet’s syndrome +/- +/- +/-
  • acneiform lesions
  • Papulo-vesiculo-pustular eruptions
  • Superficial thrombophlebitis
  • Male dominancy
  • ANA-negative
Kikuchi’s disease +/- ↑/↓
  • Transient skin rashes
  • Malar rash
  • Erythematous macules, patches, papules, or plaques
  • May be associated with SLE
Serum sickness +/- + +/-
  • pruritic rash
  • urticarial and/or serpiginous macular rash
  • Negative ANA
  • Self-limited
Psoriatic arthritis Small and large joints
Human parvovirus B19 infection + + Small joints

References

  1. Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M (2012). ""To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity". Semin. Arthritis Rheum. 41 (4): 589–98. doi:10.1016/j.semarthrit.2011.07.010. PMID 21959290.